Aarti Drugs Ltd

Aarti Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 11 August 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 September 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Aarti Drugs Ltd has witnessed a notable shift in its technical momentum, moving from a mildly bullish to a bullish stance, supported by key indicators such as MACD, moving averages, and Bollinger Bands. Despite mixed returns relative to the Sensex over various timeframes, the pharmaceutical company’s recent price action and technical signals suggest a cautiously optimistic outlook for investors.

Aarti Drugs Ltd has experienced a nuanced shift in its technical momentum, moving from a bullish to a mildly bullish trend as of late August 2026. Despite a marginal day decline of 0.10%, the stock’s technical indicators present a complex picture, with some signals pointing to strength while others suggest caution. This article analyses the recent technical parameter changes, key momentum indicators, and the stock’s performance relative to the broader market.

Aarti Drugs Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 11 August 2026. However, the analysis and financial metrics discussed below reflect the stock's current position as of 23 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Aarti Drugs Ltd has witnessed a notable shift in its technical momentum, upgrading from a mildly bullish to a bullish stance across key indicators. Despite a recent dip in price and mixed long-term returns relative to the Sensex, the pharmaceutical company’s technical parameters suggest improving momentum and potential for recovery in the near term.

The 50-day moving average for Aarti Drugs Ltd has crossed above the 200-day moving average, signalling a golden cross on 12 Aug 2026. Yet, the stock declined 1.81% on the day of the crossover, and the monthly technical indicators present a nuanced picture. This golden cross is technically valid but contextually complicated, warranting a closer look at the broader data.

Aarti Drugs Ltd has seen its investment rating upgraded from Sell to Hold as of 11 Aug 2026, driven primarily by a shift in technical indicators and an attractive valuation profile despite flat recent financial performance. The company’s stock has shown signs of mild bullish momentum, prompting a reassessment of its outlook amid mixed fundamental signals.

Aarti Drugs Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance. This change is underscored by a series of mixed but increasingly positive technical indicators, signalling a potential turnaround for the stock amid broader market challenges.

Aarti Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 21 May 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 07 August 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Aarti Drugs Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, reflecting a complex interplay of bullish and bearish signals across multiple timeframes. Despite a modest day gain of 1.77%, the small-cap pharmaceutical company faces a challenging outlook as its MarketsMOJO grade was downgraded from Hold to Sell on 21 May 2026, underscoring caution among investors amid mixed technical indicators and underwhelming long-term returns compared to the broader Sensex.

Aarti Drugs Ltd has experienced a notable shift in its technical momentum, transitioning from a sideways trend to a mildly bearish stance. Despite some bullish signals on weekly indicators, the overall technical landscape suggests caution for investors as the stock faces downward pressure amid a recent downgrade in its mojo grade to Sell.

Aarti Drugs Ltd., a prominent manufacturer of active pharmaceutical ingredients (APIs) and pharma intermediates, reported consolidated net profit of ₹50.17 crores for Q1 FY27 (June 2026 quarter), marking a decline of 9.10% quarter-on-quarter from ₹55.19 crores in Q4 FY26 and a 6.94% drop year-on-year from ₹53.91 crores in Q1 FY26. The ₹3,854-crore market capitalisation company faced headwinds from sequential profit compression despite maintaining operational margin discipline, with the stock trading at ₹423.50 as of July 31, 2026, reflecting a modest 2.64% gain on the day following the results.

Aarti Drugs Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, reflecting a complex interplay of bullish and bearish signals across key indicators. Despite a modest day gain of 1.41%, the stock’s technical profile and recent rating downgrade to a Sell by MarketsMOJO highlight a cautious outlook for investors navigating the Pharmaceuticals & Biotechnology sector.

Aarti Drugs Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite some bullish weekly signals, monthly indicators suggest caution, reflecting a complex interplay of market forces and investor sentiment as the stock trades at ₹407.25, down 0.92% from the previous close.

Aarti Drugs Ltd has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend, reflecting a complex interplay of bullish and bearish signals across key technical indicators. Despite a modest day gain of 1.58%, the stock’s broader technical picture remains mixed, with divergent signals from MACD, RSI, moving averages, and other momentum oscillators, underscoring the need for cautious investor appraisal.

Aarti Drugs Ltd is rated Sell by MarketsMOJO, with this rating last updated on 21 May 2026. However, the analysis and financial metrics discussed below reflect the stock’s current position as of 27 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Aarti Drugs Ltd, a small-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, with recent indicators signalling a transition from sideways to mildly bearish trends. Despite some bullish weekly signals, the overall technical landscape suggests caution for investors as the stock faces downward pressure amid broader market challenges.

Aarti Drugs Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 21 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 16 July 2026, providing investors with the latest insights into the company’s performance and outlook.